New in Brief: Body & Brain
<p>Second-guessing cancer treatments, a boyish side to soy and more in this week’s news</p> <p> <span class="exclusive print">Web edition</span> : Thursday, August 11th, 2011 </p> <p><strong>Two-drug therapy for lung cancer</strong><br /> Patients age 70 or older with lung cancer should get two drugs rather than the currently recommended single-drug therapy, scientists in France report online August 9 in the <em>Lancet</em>. The researchers randomly assigned 448 lung cancer patients, median age 77, to get either two standard chemotherapies or one. The double-treatment group had a median survival time of 10.3 months, and 45 percent lived longer than one year. The single-drug group survived a median of 6.2 months and only 25 percent survived a year. Despite observing more side effects in the double-therapy patients, the researchers argue that the longer survival times suggest that current treatment guidelines be reconsidered. ?<em>Nathan Seppa</em></p> <p><strong>A boyish side to
New in Brief: Body & Brain <p>Second-guessing cancer treatments, a boyish side to soy and more in this week’s news</p> <p> <span class="exclusive print">Web edition</span> : Thursday, August 11th, 2011 </p> <p><strong>Two-drug therapy for lung cancer</strong><br /> Patients age 70 or older with lung cancer should get two drugs rather than the currently recommended single-drug therapy, scientists in France report online August 9 in the <em>Lancet</em>. The researchers randomly assigned 448 lung cancer patients, median age 77, to get either two standard chemotherapies or one. The double-treatment group had a median survival time of 10.3 months, and 45 percent lived longer than one year. The single-drug group survived a median of 6.2 months and only 25 percent survived a year. Despite observing more side effects in the double-therapy patients, the researchers argue that the longer survival times suggest that current treatment guidelines be reconsidered. ?<em>Nathan Seppa</em></p> <p><strong>A boyish side to
New in Brief: Body & Brain <p>Second-guessing cancer treatments, a boyish side to soy and more in this week’s news</p> <p> <span class="exclusive print">Web edition</span> : Thursday, August 11th, 2011 </p> <p><strong>Two-drug therapy for lung cancer</strong><br /> Patients age 70 or older with lung cancer should get two drugs rather than the currently recommended single-drug therapy, scientists in France report online August 9 in the <em>Lancet</em>. The researchers randomly assigned 448 lung cancer patients, median age 77, to get either two standard chemotherapies or one. The double-treatment group had a median survival time of 10.3 months, and 45 percent lived longer than one year. The single-drug group survived a median of 6.2 months and only 25 percent survived a year. Despite observing more side effects in the double-therapy patients, the researchers argue that the longer survival times suggest that current treatment guidelines be reconsidered. ?<em>Nathan Seppa</em></p> <p><strong>A boyish side to
Pops
Newest Clips
Latest Comments
Most Pops
Print
Save
Turn on live update